Padron E - Search Results

1

Current state of prognostication and risk stratification in myelodysplastic syndromes.

Zeidan AM, Gore SD, Padron E, Komrokji RS. Zeidan AM, et al. Among authors: padron e. Curr Opin Hematol. 2015 Mar;22(2):146-54. doi: 10.1097/MOH.0000000000000110. Curr Opin Hematol. 2015. PMID: 25575032 Review.

2

Biology and treatment of the 5q- syndrome.

Padron E, Komrokji R, List AF. Padron E, et al. Expert Rev Hematol. 2011 Feb;4(1):61-9. doi: 10.1586/ehm.11.2. Expert Rev Hematol. 2011. PMID: 21322779 Review.

3

Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome.

Komrokji RS, Corrales-Yepez M, Al Ali N, Kharfan-Dabaja M, Padron E, Fields T, Lancet JE, List AF. Komrokji RS, et al. Among authors: padron e. Cancer. 2012 May 15;118(10):2659-64. doi: 10.1002/cncr.26567. Epub 2011 Sep 28. Cancer. 2012. PMID: 21956402 Free article.

4

The 5q- syndrome: biology and treatment.

Padron E, Komrokji R, List AF. Padron E, et al. Curr Treat Options Oncol. 2011 Dec;12(4):354-68. doi: 10.1007/s11864-011-0165-1. Curr Treat Options Oncol. 2011. PMID: 21964863

5

Advances in the management of myelofibrosis.

Komrokji RS, Verstovsek S, Padron E, List AF. Komrokji RS, et al. Among authors: padron e. Cancer Control. 2012 Oct;19(4 Suppl):4-15. doi: 10.1177/107327481201904s04. Cancer Control. 2012. PMID: 23042420 Free article. Review.

6

Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes.

Komrokji RS, Corrales-Yepez M, Kharfan-Dabaja MA, Al Ali NH, Padron E, Rollison DE, Pinilla-Ibarz J, Zhang L, Epling-Burnette PK, Lancet JE, List AF. Komrokji RS, et al. Among authors: padron e. Am J Hematol. 2012 Nov;87(11):1006-9. doi: 10.1002/ajh.23303. Epub 2012 Aug 1. Am J Hematol. 2012. PMID: 23090887 Free article.

7

Mayo prognostic model for WHO-defined chronic myelomonocytic leukemia: ASXL1 and spliceosome component mutations and outcomes.

Patnaik MM, Padron E, LaBorde RR, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA, Ketterling RP, Al-kali A, Pardanani A, Ali NA, Komrokji RS, Tefferi A. Patnaik MM, et al. Among authors: padron e. Leukemia. 2013 Jul;27(7):1504-10. doi: 10.1038/leu.2013.88. Epub 2013 Mar 27. Leukemia. 2013. PMID: 23531518

8

Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes.

Mishra A, Corrales-Yepez M, Ali NA, Kharfan-Dabaja M, Padron E, Zhang L, Epling-Burnette PK, Pinilla-Ibarz J, Lancet JE, List AF, Komrokji RS. Mishra A, et al. Among authors: padron e. Am J Hematol. 2013 Jul;88(7):566-70. doi: 10.1002/ajh.23454. Epub 2013 May 30. Am J Hematol. 2013. PMID: 23605934 Free PMC article.

9

GM-CSF-dependent pSTAT5 sensitivity is a feature with therapeutic potential in chronic myelomonocytic leukemia.

Padron E, Painter JS, Kunigal S, Mailloux AW, McGraw K, McDaniel JM, Kim E, Bebbington C, Baer M, Yarranton G, Lancet J, Komrokji RS, Abdel-Wahab O, List AF, Epling-Burnette PK. Padron E, et al. Blood. 2013 Jun 20;121(25):5068-77. doi: 10.1182/blood-2012-10-460170. Epub 2013 Apr 30. Blood. 2013. PMID: 23632888 Free PMC article.

10

Multikinase inhibitors for treating high-risk myelodysplastic syndromes: can this be brought into clinical practice?

Duong VH, Padron E, List AF, Komrokji RS. Duong VH, et al. Among authors: padron e. Expert Rev Hematol. 2013 Oct;6(5):485-7. doi: 10.1586/17474086.2013.827884. Epub 2013 Oct 2. Expert Rev Hematol. 2013. PMID: 24083503 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

260 results

Search Page